Welcome

PepTcell’s current priorities are the development of a new class of synthetic vaccines – T cell vaccines – against highly mutagenic viruses to prevent Influenza, HIV, Hepatitis B & C and Rotavirus infections.

In addition the company is working to identify and develop a single vaccine that will be effective against a number of mosquito borne diseases and a breast cancer drug for oestrogen positive and HER 2 Neu positive or negative cancers.